Tübingen, Germany

Guenter Jung

This inventor holds 1 USPTO granted patent. Top assignee: Diamalt Aktiengesellschaft. Active years: 1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guenter Jung. Retrieved from https://idiyas.com/inventor/guenter-jung-2akv5w7o

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guenter Jung: Innovator in Somatostatin Derivatives

Introduction

Guenter Jung is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of biochemistry, particularly through his work on somatostatin derivatives. His innovative approach has led to advancements that may impact various medical applications.

Latest Patents

Guenter Jung holds a patent for "Novel somatostatin derivatives." This patent represents his commitment to exploring new avenues in therapeutic development. The patent showcases his ability to innovate within the complex landscape of biochemical research.

Career Highlights

Throughout his career, Guenter Jung has been associated with Diamalt Aktiengesellschaft, where he has applied his expertise in biochemistry. His work at the company has allowed him to focus on developing novel compounds that could enhance medical treatments.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Guenter Jung's contributions to the field of somatostatin derivatives highlight his role as an influential inventor. His work continues to pave the way for future innovations in biochemistry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…